Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy.
A 16-year-old boy developed fever, generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium. When both drugs were discontinued, his fever and rigidity subsided and biochemical irregularities spontaneously returned to normal, without any complications. Classic neuroleptic malignant syndrome (NMS) was diagnosed. Concomitant administration of lithium with olanzapine may place patients at risk for NMS. Clinicians need to be aware of this rare but potentially fatal side effect in patients of all ages, and especially in adolescents receiving both drugs.
Berry
Neeraj
N
Department of Psychiatry, National Pharmacovigilance Centre, All India Institute of Medical Sciences, New Delhi, India.
Pradhan
Sapna
S
Sagar
Rajesh
R
Gupta
Suresh Kumar
SK
D000293:Adolescent; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001569:Benzodiazepines; D001714:Bipolar Disorder / Q000188:drug therapy*; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D006801:Humans; D008094:Lithium / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis / Q000209:etiology*; D000077152:Olanzapine; D010890:Pirenzepine / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D008094:Lithium; D000077152:Olanzapine